Wednesday, July 09, 2014 1:05:45 AM
Recent TBPH News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:15:36 PM
- Theravance Biopharma to Participate in an Upcoming Investor Conference • PR Newswire (US) • 05/09/2024 10:00:00 AM
- Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 • PR Newswire (US) • 04/29/2024 10:00:00 AM
- Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 • PR Newswire (US) • 04/10/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 09:16:00 PM
- Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:11:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:10:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:08:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:06:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:04:32 AM
- Theravance Biopharma to Participate in an Upcoming Investor Conference • PR Newswire (US) • 02/22/2024 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:12:31 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:00:32 PM
- Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 • PR Newswire (US) • 02/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 11:16:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 11:07:26 AM
- Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) • PR Newswire (US) • 01/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 11:01:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 11:09:03 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 11:06:25 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/21/2023 10:10:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:06:39 PM
- Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors • PR Newswire (US) • 12/21/2023 10:00:00 PM
- Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference • PR Newswire (US) • 12/18/2023 11:00:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM